• Incannex Healthcare posted a comprehensive loss of USD 4.35 million for quarter ended March 31, 2026, widening 7% from USD 4.06 million a year earlier.
• Operating loss narrowed 19% to USD 4.05 million as research and development costs fell 88% to USD 321,000, while general and administrative expenses climbed 64% to USD 3.73 million.
• Other income dropped to USD 165,000 from USD 1.04 million on lower gains from warrant liabilities of USD 380,000 versus USD 1.82 million.
• Cash and cash equivalents rose to USD 74.5 million at March 31, 2026 from USD 15 million at June 30, 2025, following a March registered direct offering that raised about USD 10 million in gross proceeds.
• Pipeline update highlighted IHL-42X in a Phase 2 crossover dose-optimization study ahead of a planned Phase 3 program, while PSX-001 advanced with FDA clearance for a Phase 2b dose-comparison study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-057227), on May 15, 2026, and is solely responsible for the information contained therein.